--- title: "CRISPR Therapeutics (CRSP): news, pipeline and catalysts" url: "https://aibio.space/companies/crispr-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CRISPR Therapeutics news for investors: CRISPR Therapeutics makes gene editing medicines, including the approved sickle cell and beta thalassemia therapy…" --- Desk view · Opinion · Updated Oct 22, 2026 ## CRISPR Therapeutics has its product; the bet now is one-time liver editing CRISPR Therapeutics has an approved product with fast-rising sales and enough cash to fund years of work. Its larger value case rests on one-time liver editing for common heart disease, where the data are encouraging but come from very few patients. Read the full desk view aibio.space Investor Rank · Opinion **6** /10 Neutral view Casgevy is approved with rising sales and $2.36 billion of cash, but most programs are in phase 1 and the in vivo liver editing data come from few patients. - **Technology**: 1/2 - **Odds**: 0/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Proven ex vivo, promising in vivo.** Casgevy is approved, and one CTX310 infusion cut LDL 53% on average at one year in a small trial. - **Odds**: **Early outside Casgevy.** Most programs are in phase 1, where base rates put approval odds near 8%. - **Balance sheet**: **Well funded.** The company held $2.36 billion at June 30, 2026, against a $91.2 million quarterly loss. - **Main risk**: **Unproven one-time editing.** A late safety signal in liver editing would hit CTX310, CTX340 and CTX460 together. - **Watch next**: **AHA late-breaker on November 9.** Phase 1b CTX310 data will show whether a fixed dose gives consistent results. ## Top news on CRISPR ## Dates **November 8, 2026** Zugo-cel poster in refractory systemic sclerosis at ACR Convergence 2026 [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-clinical-data-zugocabtagene-geleucel) **November 9, 2026** CTX310 phase 1b severe hypertriglyceridemia data, late-breaker at AHA Scientific Sessions [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-late-breaking-data-american-heart-0) **2H 2026** CTX611 phase 2 update and zugo-cel autoimmune and oncology updates [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) **2026** CTX321 Lp(a) program update [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) ## The money $2,364.4 million in cash, cash equivalents and marketable securities at June 30, 2026 (Q2 2026). The 10-Q says the company expects its cash to fund operations for at least 24 months. [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) Casgevy revenue of $76 million in Q2 2026 (booked by Vertex); CRISPR's own total revenue was $10.2 million. [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) ## Risks on the record - Casgevy requires stem cell collection and chemotherapy conditioning; all treated patients had grade 3 or 4 neutropenia and thrombocytopenia, which limits uptake speed. [Source](https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment) - CTX310 one-year data come from 15 patients, with only four at the top dose and wide response ranges. [Source](https://www.hcplive.com/view/ctx310-gene-editing-sustains-angptl3-ldl-cuts-1-year) - $600.0 million aggregate principal of convertible notes mature on March 1, 2031 unless converted at about $76.56 per share, per the 10-Q. The pricing release had said $550 million. [Source](https://www.biospace.com/press-releases/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering) ## Questions investors ask ### What is aibio.space's Investor Rank for CRISPR Therapeutics? 6 out of 10, our neutral view. Casgevy is approved with rising sales and $2.36 billion of cash, but most programs are in phase 1 and the in vivo liver editing data come from few patients. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### How much revenue does Casgevy make? CRISPR Therapeutics said Casgevy revenue was $76 million in the second quarter of 2026, up 151% from a year earlier. Vertex books the sales, and CRISPR's own revenue line was $10.2 million. [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) ### What is CTX310 and does it work? CTX310 is a one-time in vivo CRISPR therapy that switches off the ANGPTL3 gene in the liver. In a 15-patient phase 1a trial, the top dose cut LDL 53% and triglycerides 48% on average at one year. [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-presents-phase-1a-data-ctx310r-demonstrating/) ### How much cash does CRISPR Therapeutics have? The company reported $2,364.4 million in cash, cash equivalents and marketable securities at June 30, 2026. That includes $585.4 million in net proceeds from convertible notes sold in March 2026. [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) ### Who is the CFO of CRISPR Therapeutics? A.J. Silver became CFO on October 19, 2026, after Raju Prasad stepped down to pursue external opportunities. Silver had been senior vice president of finance since January 2025. [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-chief-financial-officer-transition) ### Is Casgevy approved for children? Yes. On July 1, 2026, the FDA expanded Casgevy's U.S. approval to patients aged 2 and older with sickle cell disease with recurrent pain crises or transfusion-dependent beta thalassemia. Vertex said about 5,500 more children became eligible. [Source](https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment) ### What is CRISPR Therapeutics's market cap? We do not publish live share prices. In its annual report, CRISPR Therapeutics AG put the market value of shares held by non-affiliates (public float) at $4.10 billion as of Jun 30, 2025. Source ### Is CRISPR Therapeutics a smaller reporting company? SEC records list CRISPR Therapeutics AG's filer category as: Large accelerated filer. Source ### Where is CRISPR Therapeutics headquartered? SEC records list its business address as BAARERSTRASSE 14, ZUG. Source ### When does CRISPR Therapeutics's fiscal year end? CRISPR Therapeutics AG's fiscal year ends on December 31, per SEC records. Source ### What did CRISPR Therapeutics last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-10-19. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/crsp-20261019.htm) ### What was CRISPR Therapeutics called before? SEC records list these former names: CRISPR Therapeutics AG. Source ### What industry is CRISPR Therapeutics in? Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source ## Legal and investor matters Checked against CRISPR Therapeutics filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. CRISPR Therapeutics' 10-Q filed 2026-08-03 (Part II, Item 1) says there are currently no claims or actions pending against it that, in management's opinion, are likely to have a material adverse effect on its business, and that there were no material developments in the legal proceedings disclosed in its 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm) 1. 2026-08-03 Litigation ToolGen patent suit over Casgevy: CRISPR Therapeutics dismissed as defendant ToolGen, Inc. sued CRISPR Therapeutics and other third parties in the fourth quarter of 2025, alleging that CASGEVY infringes a ToolGen patent relating to CRISPR/Cas9 gene editing. The 10-Q filed 2026-08-03 says CRISPR Therapeutics was dismissed from the lawsuit as a defendant in April 2026, without prejudice. The filing does not name the court or give a case number, and does not say whether the suit continues against others. Status: dismissed [CRISPR Therapeutics Form 10-Q (2026-08-03)](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm) 2. 2026-03-16 Financing CRISPR Therapeutics completes $600 million convertible notes offering On 2026-03-16 CRISPR Therapeutics completed a private offering of $600.0 million of Convertible Senior Notes due 2031, including the initial purchasers' full exercise of a $50.0 million option. Net proceeds were about $585.2 million, for general corporate purposes. The notes mature on 2031-03-01. Investors agreed to an effective coupon of 1.125%, and the company raised the coupon to 1.7308% to offset anticipated 35% Swiss withholding tax on interest. [CRISPR Therapeutics Form 8-K](https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/crsp-20260316.htm) 3. 2025-10-15 Financing CRISPR Therapeutics files for up to $600 million at-the-market share sales On 2025-10-15 CRISPR Therapeutics filed a prospectus supplement to sell common shares from time to time through Jefferies as sales agent, under its 2019 Open Market Sale Agreement. The additional shares have an aggregate offering price of up to $600,000,000. They are offered under the company's automatic shelf registration statement filed 2024-08-05. [CRISPR Therapeutics Form 8-K](https://www.sec.gov/Archives/edgar/data/1674416/000119312525240282/crsp-20251015.htm) 4. 2025-05-19 Other CRISPR Therapeutics signs Sirius deal, issuing about $70 million in shares On 2025-05-19 CRISPR Therapeutics signed a collaboration, option and license agreement with Sirius Therapeutics on siRNA technology targeting Factor XI. As upfront consideration it agreed to issue about $70.0 million of its common shares (1,842,105 shares) and pay $25.0 million in cash to Sirius. Sirius also granted options to exclusively license its siRNA technology for up to two licensed targets. [CRISPR Therapeutics Form 8-K](https://www.sec.gov/Archives/edgar/data/1674416/000095017025074428/crsp-20250519.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Casgevy (exa-cel), with Vertex | Sickle cell disease and transfusion-dependent beta thalassemia, ages 2 and older in the U.S. | Approved (39 countries) [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) | | CTX310 (ANGPTL3, in vivo) | Severe hypertriglyceridemia and refractory hypercholesterolemia | Phase 1b [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-presents-phase-1a-data-ctx310r-demonstrating/) | | Zugo-cel (allogeneic CD19 CAR T) | Autoimmune diseases; B-cell malignancies | Phase 1 (autoimmune), phase 1/2 (oncology) [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) | | CTX611 (Factor XI siRNA, with Sirius) | Thrombosis prevention after total knee arthroplasty | Phase 2 [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) | | CTX340 (AGT, in vivo) | Refractory hypertension | Phase 1 [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) | | CTX460 (SERPINA1, SyNTase) | Alpha-1 antitrypsin deficiency | Phase 1 [Source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) | Opinion · Devil's advocate ## Fact-check-o-meter Consistent Messaging tracks the filings; the real caveats are that CTX310 is early and Casgevy sales are not CRISPR's revenue CRISPR Therapeutics' second-quarter release and 10-Q agree on cash and the note proceeds, and the 10-Q alone gives the runway and the legal record. The main things to keep in view are not gaps between documents: the CTX310 efficacy data come from a 15-person open-label dose-escalation study whose primary endpoint was safety, and the $76 million Casgevy figure is Vertex-booked revenue, not the company's own. 1. Science · weight medium CTX310: open-label, 15 participants, safety was the primary endpoint **The company said:** "a mean reduction from baseline of 79% (maximum 89%), a mean reduction in triglycerides (TG) of 48% (maximum 78%), and a mean reduction of low-density lipoprotein (LDL) of 53% (maximum 84%) at the highest dose" [source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-presents-phase-1a-data-ctx310r-demonstrating/) **The record says:** The same release says phase 1a "was an open label, dose-escalation trial" in which doses were given to "15 participants across sequential cohorts", and that the trial "was designed to evaluate safety and tolerability as primary endpoints, with changes in circulating ANGPTL3 protein, TG, and LDL as secondary endpoints." The ongoing CTX310 trial record on ClinicalTrials.gov is single group with no masking and a primary outcome of dose-limiting toxicities and adverse events up to 12 months. [source](https://clinicaltrials.gov/study/NCT07491172) **Our view:** The release is upfront about the design. The headline figures are means at the top dose from a small, uncontrolled group, and the mean-to-maximum gaps (53% versus 84% for LDL) show wide spread between patients. The text reviewed does not say how many participants received the top dose, which matters for how much weight 53% can bear. 2. Press release vs filing · weight low Casgevy's $76 million is Vertex-booked; CRISPR reported $10.2 million of revenue **The company said:** "CASGEVY generated second quarter 2026 revenue of $76 million, representing 78% growth quarter-over-quarter and 151% growth year-over-year." [source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) **The record says:** The 10-Q income statement shows total revenue of $10,181 thousand for the quarter, of which collaboration revenue was $10,000 thousand and grant revenue $181 thousand. It also shows "$40.3 million" of collaboration expense, net, related to the Vertex Hemoglobinopathy Agreements. The release explains the profit split in its collaboration description: "Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis." [source](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm) **Our view:** The release is accurate and says elsewhere that Vertex commercializes the drug. A skimming reader could still take $76 million as the company's top line. CRISPR still carried a net collaboration expense in the quarter, so Casgevy has not yet turned into a profit contribution in these statements. 3. Press release vs filing · weight low Cash and runway: the release gives the balance, the 10-Q gives the runway and the debt **The company said:** "The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses." [source](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) **The record says:** The 10-Q puts cash, equivalents and marketable securities at $2,364.4 million, with about $308.1 million held outside the United States, and says the company expects them "will enable us to fund our operating expenses and capital expenditures for at least the next 24 months without giving effect to any additional proceeds we may receive under our license agreements and collaborations". The notes are $600.0 million in principal, unsecured, and mature on March 1, 2031 unless earlier converted, redeemed or repurchased. [source](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm) **Our view:** The two documents agree, and neither contains going-concern language. The release does not state a runway; the 10-Q's 24 months is the only stated runway, and it excludes any partner proceeds. 4. Legal and disclosure record · weight low ToolGen patent suit: company dismissed without prejudice in April 2026 **The record says:** Item 1 of the Q2 2026 10-Q says that "in the fourth quarter of 2025, ToolGen, Inc., or ToolGen, initiated a lawsuit against us and other third parties alleging patent infringement by CASGEVY of a ToolGen patent relating to CRISPR/Cas9 gene editing technology. We were subsequently dismissed from the lawsuit as a defendant in April 2026 without prejudice." It adds that "There are currently no claims or actions pending against us that, in the opinion of our management, are likely to have a material adverse effect on our business." The 10-K (filed February 12, 2026) Item 3 describes the same suit and says patent offices may host inter partes proceedings on its intellectual property. No securities litigation or enforcement is disclosed in the latest filing. The filing does not name the court. [source](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm) **Our view:** A dismissal without prejudice means the claim could in principle be refiled, and the 10-Q says the outcome of such matters is inherently uncertain. Nothing else is disclosed as pending. Documents we compared - [CRISPR Therapeutics Q2 2026 results press release](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-15) 2026-08-03 - [CRISPR Therapeutics Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm) 2026-08-03 - [CRISPR Therapeutics Form 10-K for year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm) 2026-02-12 - [CRISPR Therapeutics press release: CTX310 durability data at ESC 2026](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-presents-phase-1a-data-ctx310r-demonstrating/) 2026-08-28 - [ClinicalTrials.gov NCT07491172 (CTX310)](https://clinicaltrials.gov/study/NCT07491172) 2026-09-18 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CRSP on TradingView](https://www.tradingview.com/symbols/NASDAQ-CRSP/). ## SEC filings and registration - **SEC name**: CRISPR Therapeutics AG - **CIK**: 1674416 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CRSP (Nasdaq) - **State or country of incorporation**: V8 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: BAARERSTRASSE 14, ZUG - **Phone**: 6173154600 - **Shares outstanding**: 96,692,653 as of 2026-07-31 (10-Q filed 2026-08-03) - **Former names**: CRISPR Therapeutics AG ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/crsp-20261019.htm) filed 2026-10-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/crsp-20260630.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/crsp-20260803.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1674416/000119312526257593/crsp-20260604.htm) filed 2026-06-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1674416/000119312526204188/crsp-20260331.htm) filed 2026-05-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/crsp-20260504.htm) filed 2026-05-04 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1674416/000119312526165158/crsp-20260421.htm) filed 2026-04-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/crsp-20260316.htm) filed 2026-03-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001674416), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/crispr-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CRISPR Therapeutics (CRSP): news, pipeline and catalysts", 2026-10-31, https://aibio.space/companies/crispr-therapeutics/